You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Braintree Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for BRAINTREE, and when can generic versions of BRAINTREE drugs launch?

BRAINTREE has nine approved drugs.

There are five US patents protecting BRAINTREE drugs.

Summary for Braintree

US Patents:	5
Tradenames:	10
Ingredients:	9
NDAs:	9

Drugs and US Patents for Braintree

+ Get email alerts for changes to this table

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Braintree Labs	SUTAB	magnesium sulfate; potassium chloride; sodium sulfate	TABLET;ORAL	213135-001	Nov 10, 2020		RX	Yes	Yes	10,143,656	⤷ Subscribe	Y			⤷ Subscribe
Braintree Labs	SUTAB	magnesium sulfate; potassium chloride; sodium sulfate	TABLET;ORAL	213135-001	Nov 10, 2020		RX	Yes	Yes	11,638,697	⤷ Subscribe	Y			⤷ Subscribe
Braintree	NULYTELY	polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride	FOR SOLUTION;ORAL	019797-001	Apr 22, 1991	AA	RX	Yes	Yes		⤷ Subscribe				⤷ Subscribe
Braintree Labs	SUTAB	magnesium sulfate; potassium chloride; sodium sulfate	TABLET;ORAL	213135-001	Nov 10, 2020		RX	Yes	Yes	11,033,498	⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Braintree

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Braintree	HALFLYTELY	bisacodyl; polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride	FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL	021551-003	Jul 16, 2010	7,291,324	⤷ Subscribe
Braintree Labs	SUPREP BOWEL PREP KIT	magnesium sulfate; potassium sulfate; sodium sulfate	SOLUTION;ORAL	022372-001	Aug 5, 2010	6,946,149	⤷ Subscribe
Braintree	AXID	nizatidine	SOLUTION;ORAL	021494-001	May 25, 2004	6,930,119	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for BRAINTREE drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	For Oral Solution and Delayed-release Tablet	210 g, 5.6 g, 0.74 g, 2.86 g and 5 mg (1 Tablet Regimen)	➤ Subscribe	2010-07-30
➤ Subscribe	Oral Solution	17.5 g/3.13 g/1.6 g per bottle	➤ Subscribe	2010-11-08
➤ Subscribe	For Oral Solution and Delayed-	210 g, 5.6 g, 0.74 g, 2.86 g and 5 mg	➤ Subscribe	2008-01-28
➤ Subscribe	Oral Solution	15 mg/mL	➤ Subscribe	2008-05-14

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.